{"transactions":[{"id":1868880,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:00:32.000Z","date":"2023-06-01","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":34.5633,"value":1728165.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A total of 50,000 shares were sold at an average price of 34.5633 in multiple transactions ranging from 34.50 to 35.02  Details of the specific transactions are available upon request."}],"balance_after":3500000,"source":{"system":"sec-edgar","filing":"0001859061-23-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906123000007/primary_doc.xml","form_type":"4"}},{"id":1868879,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:00:32.000Z","date":"2023-05-31","kind":"sale","planned":false,"acquired":false,"shares":75000,"price":33.81,"value":2535750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"A total of 75,000 shares were sold at an average price of 33.81 in multiple transactions ranging from 33.44 to 34.43.  Details of the specific transactions are available upon request."}],"balance_after":3550000,"source":{"system":"sec-edgar","filing":"0001859061-23-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906123000007/primary_doc.xml","form_type":"4"}},{"id":1888205,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-17T11:13:18.000Z","date":"2023-05-12","kind":"sale","planned":false,"acquired":false,"shares":25000,"price":33.84,"value":846000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"A total of 25,000 shares were sold at an average price of 33.84 in multiple transactions in a range of 33.50 to 34.50.  Details of the specific transactions are available upon request."}],"balance_after":3625000,"source":{"system":"sec-edgar","filing":"0001859061-23-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906123000006/primary_doc.xml","form_type":"4"}},{"id":1897756,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T21:19:30.000Z","date":"2023-05-09","kind":"sale","planned":false,"acquired":false,"shares":150000,"price":34.5048,"value":5175720.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A total of 150,000 shares were sold at an average price of 34.508 in multiple transactions in a range of 33.61 to 35.64. Details of the specific transactions are available upon request."}],"balance_after":3650000,"source":{"system":"sec-edgar","filing":"0001859061-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906123000005/primary_doc.xml","form_type":"4"}},{"id":1897755,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T21:19:30.000Z","date":"2023-05-08","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":33.9931,"value":3399310.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"A total of 100,000 shares were sold at an average price of 33.9931 in multiple transactions in a range of 33.01 to 34.855. Details of the specific transactions are available upon request."}],"balance_after":3800000,"source":{"system":"sec-edgar","filing":"0001859061-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906123000005/primary_doc.xml","form_type":"4"}},{"id":1913100,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-26T12:36:59.000Z","date":"2023-04-20","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":29.1188,"value":5823760.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"A total of 200,000 shares were sold at an average price of 29.1188 in multiple transactions in a range of 28.85 to 29.495.  Details of the specific transactions are available upon request"}],"balance_after":3900000,"source":{"system":"sec-edgar","filing":"0001859061-23-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906123000004/primary_doc.xml","form_type":"4"}},{"id":1923401,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-06T23:31:22.000Z","date":"2023-03-31","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":31.25,"value":6250000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64.  Additional details of the individual transactions are available upon request."}],"balance_after":4100000,"source":{"system":"sec-edgar","filing":"0001859061-23-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906123000003/primary_doc.xml","form_type":"4/A","original_submission_date":"2023-03-31"}},{"id":1923400,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-06T22:43:47.000Z","date":"2023-03-31","kind":"sale","planned":false,"acquired":true,"shares":200000,"price":31.25,"value":6250000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"A total of 200,000 shares were sold at an average price of 31.25 in multiple transactions ranging in price from 30.87 to 31.64"}],"balance_after":4100000,"source":{"system":"sec-edgar","filing":"0001859061-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906123000002/primary_doc.xml","form_type":"4"}},{"id":2177797,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-19T10:56:16.000Z","date":"2022-08-16","kind":"purchase","acquired":false,"shares":30684,"price":13.872,"value":425648.448,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold in multiple transaction in a range of prices from 13.65 to 14.01 and an average price of 13.872.  Details of the specific trades are available upon request"}],"balance_after":4300000,"source":{"system":"sec-edgar","filing":"0001859061-22-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906122000002/primary_doc.xml","form_type":"4"}},{"id":2202538,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-25T23:16:25.000Z","date":"2022-07-21","kind":"sale","acquired":false,"shares":34658,"price":11.21,"value":388516.18,"ownership":{"direct":true},"balance_after":4330684,"source":{"system":"sec-edgar","filing":"0001859061-22-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185906122000001/primary_doc.xml","form_type":"4"}},{"id":2219925,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T11:51:44.000Z","date":"2022-06-24","kind":"sale","acquired":false,"shares":34658,"price":11.76,"value":407578.08,"ownership":{"direct":true},"balance_after":4365342,"source":{"system":"sec-edgar","filing":"0001856641-22-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000185664122000001/primary_doc.xml","form_type":"4"}},{"id":2562579,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":112774,"kind":"organization","name":"A2A Pharmaceuticals, Inc.","position":1,"cik":"0001859061","reported_name":"A2A Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-21T20:05:18.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":34658,"price":10.96,"value":379851.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by A2A Pharmaceuticals Inc. Sotirios Stergiopoulos is a member of the Issuer's Board of Directors and is an affiliate of the Reporting Person."}],"balance_after":4400000,"source":{"system":"sec-edgar","filing":"0000899243-21-036769","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840439/000089924321036769/doc4.xml","form_type":"4"}}]}